What is ArriVent BioPharma, Inc.'s (AVBP) StockRank?

MoatMap's StockRank for ArriVent BioPharma, Inc. (AVBP) is 41/100, with a Hold signal. This is a composite score combining Quality (37), Value (26), and Momentum (70) factor ranks across MoatMap's 20,000+ stock universe.

Does ArriVent BioPharma, Inc. have an economic moat?

ArriVent BioPharma, Inc. (AVBP) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is ArriVent BioPharma, Inc. a buy, hold, or sell?

MoatMap's current signal for ArriVent BioPharma, Inc. (AVBP) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is ArriVent BioPharma, Inc. in?

ArriVent BioPharma, Inc. (AVBP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

AVBP

HOLDREMOVE

ArriVent BioPharma, Inc. · Healthcare · United States · $1.3B · Avg Vol: $16M/d

StockRank

P/E (TTM)

—

ROE

-55.2%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

As a clinical-stage biopharmaceutical company, it lacks the established cash flows, high ROIC, and structural moats required by our investment philosophy, and is highly vulnerable to funding cycles.

COMPANY DESCRIPTION

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer, particularly in areas with high unmet medical need, with a lead candidate targeting specific mutations in non-small cell lung cancer. The company relies on its scientific expertise in precision oncology and strategic partnerships to advance its pipeline. It is a focused biopharma company specializing in precision oncology, with a pipeline aimed at specific genetic targets in cancer.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-1.15	-2.17	-2.56	-4.32	—
Shares	32.0M	32.0M	33.7M	42.5M	+32.8%
Debt	0.1M	0.3M	0.2M	14,000	-53.5%
Equity	-85.1M	-153.2M	257.7M	307.2M	19.2%
Op CF	-43.6M	-55.8M	-70.2M	-160.6M	—
Inv CF	0	0	-192.5M	-71.2M	—
Fin CF	169.7M	42.9M	186.6M	203.1M	—

PRICE (1Y)+10.0%

SMA 50SMA 200

$31.74

RSI (14)

57.4

52W High

$33.62

From 52W High

0.9%

SCORE BREAKDOWN

Quality

ROIC

-57.8%11.8

ROE

-55.2%15.7

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-24.9%12.5

Piotroski

29.2

Int. Cover

—N/A

D/E Ratio

0.00x97.1

Current Ratio

13.95x91.8

Value

P/E (TTM)

—N/A

EV/EBITDA

—N/A

P/FCF

—N/A

P/B

4.3x28.3

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

94%93.8

RS 6M

26%89.3

SMA 50/200

1.26x92.1

EPS Rev 4W

-9.2%9.0

EPS Rev 12W

+9.1%61.8

EPS Improve

-3%19.6

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$1.3B

P/E (Forward)

-8.8x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVBP are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
AVBP	ArriVent BioPharma, Inc.(you)	$1.3B	41	HOLD
CAPR	Capricor Therapeutics, Inc.	$1.7B	40	HOLD
ABSI	Absci Corporation	$948M	42	HOLD
ARDX	Ardelyx, Inc.	$1.5B	45	HOLD
ZYME	Zymeworks Inc.	$1.9B	40	HOLD
FTRE	Fortrea Holdings Inc.	$1.4B	47	HOLD
GERN	Geron Corporation	$802M	41	HOLD
JBIO	Jade Biosciences, Inc.	$1.0B	34	SELL
TYRA	Tyra Biosciences, Inc.	$1.9B	38	HOLD
CRVS	Corvus Pharmaceuticals, Inc.	$1.1B	33	SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

ArriVent BioPharma, Inc. (AVBP) — Stock Score Summary

ArriVent BioPharma, Inc. (AVBP) has a MoatMap StockRank of 41/100 based on Quality (37/100), Value (26/100), and Momentum (70/100) factor scores. The current signal is HOLD. As a clinical-stage biopharmaceutical company, it lacks the established cash flows, high ROIC, and structural moats required by our investment philosophy, and is highly vulnerable to funding cycles.

Key Financial Metrics

Price	$31.74
Market Cap	$1.3B
P/E (Forward)	-8.78
Price/Book	4.27
Return on Equity	-55.2%
Return on Invested Capital	-57.8%
Debt/Equity	0.13
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-83M

ArriVent BioPharma, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is ArriVent BioPharma, Inc.’s (AVBP) StockRank?: MoatMap’s StockRank for ArriVent BioPharma, Inc. (AVBP) is 41/100, with a Hold signal. It is a composite of Quality (37), Value (26), and Momentum (70) factor ranks across MoatMap’s 20,000+ stock universe.
Does ArriVent BioPharma, Inc. have an economic moat?: ArriVent BioPharma, Inc. (AVBP) has a Quality factor score of 37/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is ArriVent BioPharma, Inc. a buy, hold, or sell?: MoatMap’s current signal for ArriVent BioPharma, Inc. (AVBP) is Hold, based on a StockRank of 41/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is ArriVent BioPharma, Inc. in?: ArriVent BioPharma, Inc. (AVBP) operates in the Healthcare sector, specifically the Biotechnology industry (United States).